This timing puts the company directly in the middle of a significant
medical need ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏



 

[Morning Watchlist]
[[link removed]]

Tuesday, October 6, 2026  •  Your Daily Market Briefing

You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS.
If you no longer wish to receive these emails, please unsubscribe here
[[link removed]].

Sponsored Content

Sponsored by Interactive Offers.

This information has been disseminated on behalf of NanoViricides,
Inc.

NANOVIRICIDES IS STEPPING INTO THE SPOTLIGHT WITH A POTENTIAL
CATALYST TO WATCH AS EBOLA EXPLODES IN THE DRC AND ITS ORAL NV-387
ANTIVIRAL IS SET TO ENTER A PHASE II TRIAL!

[[link removed]]

WITH A FAST-GROWING EBOLA OUTBREAK CARRYING A CRUDE FATALITY RATE
ABOVE 48%, NNVC IS MOVING NV-387 INTO THE CLINIC WHILE A SECOND
POTENTIAL APPLICATION IN RESURGENT MEASLES ADDS ANOTHER CATALYST TO
THE STORY

Greetings,

Sometimes a small-cap biotech story gets interesting because of a
promising drug candidate. And sometimes the opportunity becomes even
more compelling when that candidate is moving toward a clinical trial
_at the exact moment_ a major unmet medical need is escalating.

THAT IS THE SETUP DEVELOPING AROUND NANOVIRICIDES, INC. (NYSE
AMERICAN: NNVC). [[link removed]]

NNVC announced September 15 that its PHASE II CLINICAL TRIAL OF
NV-387 ORAL GUMMIES AS A TREATMENT FOR EBOLA is scheduled to begin
this month in the Democratic Republic of Congo (DRC), targeting the
ongoing outbreak of Bundibugyo ebolavirus. 

The timing is significant. According to the World Health
Organization, the DRC outbreak had reached 6,757 CONFIRMED CASES AND
3,267 DEATHS AS OF SEPTEMBER 7, representing a crude case-fatality
ratio of 48.3%. WHO also reported that the outbreak had expanded to 61
HEALTH ZONES ACROSS SIX PROVINCES. 

For NNVC, the upcoming trial represents something investors will want
to watch closely: a real-world test of NV-387 against a serious viral
disease, while the same drug candidate is simultaneously being
developed for additional viral targets — INCLUDING MEASLES AND MPOX!


Phase 2 matters a lot, especially for a small biotech like NNVC,
because it means the drug is moving beyond early safety testing and
into a stage where researchers are looking more seriously at whether
the drug actually works in patients.

NV-387 IS HEADING INTO THE CLINIC

The biggest near-term development for NNVC is unquestionably the
planned Ebola trial.

NANOVIRICIDES [[link removed]] says the first Ebola
patient could receive NV-387 Oral Gummies as early as next week,
barring logistical impediments caused by the outbreak itself. 

The planned study is an adaptive Phase IIA/IIB trial, beginning with
a safety and dose run-in before moving into a randomized, controlled
efficacy evaluation. 

That transition from laboratory and animal research into human
clinical testing is an important milestone for any biotechnology
company.

WHAT MAKES THE STORY PARTICULARLY INTERESTING IS _HOW_ NV-387 IS
ADMINISTERED.

NNVC says NV-387 is currently the only orally administered drug in
clinical trials as a treatment for Ebola, to the company's knowledge.
Other therapies being studied in the DRC include treatments delivered
by infusion. 

In an outbreak occurring across resource-limited areas, the potential
advantages of an oral treatment are straightforward: administration
could potentially be simpler and more scalable than therapies
requiring intravenous delivery.

THIS IS A POTENTIALLY IMPORTANT CLINICAL CATALYST TO WATCH!

A MAJOR UNMET MEDICAL NEED

The backdrop to the trial is difficult to ignore.

WHO says the current Bundibugyo virus outbreak has become the LARGEST
EBOLA OUTBREAK EVER REPORTED IN THE DRC, with sustained transmission
and geographic expansion. As of September 7, cases had been reported
across 61 health zones, with Ituri remaining the epicenter. 

WHO has also classified the risk within the DRC as _very high_, while
the risk to countries sharing land borders with the DRC remains
high. 

Importantly, WHO notes that the Bundibugyo species involved in the
current outbreak is one for which there is NO SPECIFIC TREATMENT OR
VACCINE, although potential interventions are being studied. 

That creates an unusually relevant environment for an antiviral
candidate entering a clinical trial.

For NNVC [[link removed]], the question is no longer
simply whether NV-387 can demonstrate activity in preclinical models.
THE NEXT QUESTION IS WHETHER THAT ACTIVITY CAN TRANSLATE INTO
MEANINGFUL RESULTS IN HUMAN EBOLA PATIENTS.

That is the catalyst to have on radar.

WHY NV387 IS DIFFERENT

At the heart of the NNVC story is the company's NANOVIRICIDE
TECHNOLOGY.

NanoViricides describes NV-387 as a broad-spectrum antiviral designed
around a host-mimetic approach. Rather than relying solely on
targeting a highly variable viral feature, the company's technology is
designed to mimic features on host cells that viruses use during
infection. 

THE COMPANY BELIEVES THIS APPROACH COULD MAKE IT MORE DIFFICULT FOR
VIRUSES TO ESCAPE THROUGH MUTATION.

NNVC also points to prior animal-model work in which oral NV-387
outperformed intravenous remdesivir in extending survival in a lethal
coronavirus infection model. The company believes this provides
additional support for advancing the drug into human testing against
Ebola. 

THE UPCOMING EBOLA TRIAL WILL PROVIDE A MUCH MORE IMPORTANT TEST!

MEASLES IS ANOTHER POTENTIAL CATALYST

WHILE EBOLA IS THE IMMEDIATE CATALYST, MEASLES COULD GIVE THE NV-387
STORY ANOTHER MAJOR DIMENSION.

NNVC [[link removed]] announced in August that it is
preparing for a Phase II clinical trial program evaluating NV-387 as a
treatment for measles. 

The company cited 2,903 CONFIRMED MEASLES CASES IN THE UNITED STATES
AS OF AUGUST 27, 2026, compared with 2,289 confirmed cases during all
of 2025. 

The company also highlighted significant measles activity
internationally, including an expanding outbreak in Bangladesh.

And there is a particularly interesting regulatory angle here.

THE FDA HAS GRANTED NV-387 BOTH ORPHAN DRUG DESIGNATION AND RARE
PEDIATRIC DISEASE DRUG DESIGNATION FOR MEASLES, ACCORDING TO
NANOVIRICIDES. 

The Rare Pediatric Disease designation can make the company eligible
for a PRIORITY REVIEW VOUCHER if the drug ultimately receives
marketing approval for the qualifying indication and all applicable
requirements are satisfied. 

A Priority Review Voucher can potentially have significant commercial
value because it can be used to obtain priority review for another
qualifying drug application or, subject to applicable rules,
potentially transferred.

NNVC itself notes that a PRV would only become available if the
required conditions are met following successful development and
approval.

MULTIPLE VIRAL TARGETS

One of the more intriguing aspects of NNVC is that it isn't building
its story around a single disease.

The company identifies NV-387 as its lead broad-spectrum antiviral
candidate and is developing it across multiple potential applications,
including EBOLA, MPOX, MEASLES, RSV, INFLUENZA AND CORONAVIRUS-RELATED
INFECTIONS. 

The company is also developing NV-HHV-1 for shingles.

That gives investors multiple potential clinical and regulatory
catalysts to follow rather than a single binary event.

The Ebola program, however, stands out because it is now approaching
human testing against an active outbreak where the medical need is
substantial.

IN SUMMARY

NANOVIRICIDES [[link removed]] is entering an
important phase of its development.

The company has a broad-spectrum antiviral candidate moving toward a
PHASE II CLINICAL TRIAL FOR EBOLA IN THE DRC, right as the Bundibugyo
outbreak continues to expand. WHO's latest available data show
thousands of confirmed cases and deaths, with a crude fatality ratio
above 48%. 

At the same time, the company is preparing a clinical development
program for MEASLES, another viral disease experiencing renewed
outbreaks globally. 

NV-387 has already received FDA Rare Pediatric Disease Drug
Designation for measles, creating the possibility of a future Priority
Review Voucher if the drug ultimately meets the applicable
requirements for approval. 

THE UPCOMING EBOLA TRIAL IS AN IMPORTANT EVENT FOR NNVC.

NNVC is a name worth putting on the radar now because NV-387 is
moving from potential to clinical testing, with Ebola as the immediate
catalyst and measles providing another potentially important avenue
for development.

THE NEXT CHAPTER COULD BEGIN WITH THE FIRST PATIENT DOSED IN THE
EBOLA TRIAL!

KEEP AN EYE ON DEVELOPMENTS! [[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

This is a paid advertisement for NanoViricides, Inc. (NNVC).  Behind
the Markets will receive compensation from Interactive Offers in
connection with multiple mailings for this advertisement. Behind the
Markets is paid a fixed cash fee for multiple mailings for this
advertisement in the amount of $7,500. This communication is for
informational and advertising purposes only and does not constitute
investment advice, an offer, or a recommendation to buy or sell any
security. Investors should conduct their own independent research and
consult a qualified financial professional before investing. 

This disclosure is made as of 10/06/2026. 

You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these emails, please unsubscribe here
[[link removed]].

For more information about our privacy practices, please review our
Privacy Policy
[[link removed]]
or our Legal Notices
[[link removed]].

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Visit our website here: Behind the Markets
[[link removed]]

Copyright © 2026 Behind the Markets, LLC, All rights reserved.